Will Maier

Will Maier has a diverse and extensive work experience in the pharmaceutical and healthcare industry. Currently, they hold the position of Vice President, Rare Disease, Drug Development Sciences at ICON plc, a role they have been in since January 2021. Prior to that, they served as the Chief Scientific Officer at ICON plc (formerly Aptiv Solutions) from January 2018 to December 2020. Before joining ICON plc, they worked at Mapi Group as the Chief Scientific Officer from April 2008 to December 2017, where they were responsible for business development, scientific leadership, and international partnerships. Will also worked as a Consultant at Bayer HealthCare from July 2006 to December 2015, Takeda Pharmaceuticals from August 2011 to April 2015, Sigma-tau from August 2010 to March 2014, Lundbeck from April 2009 to June 2011, Amgen from 2007 to 2010, Spectrum Pharmaceuticals from 2006 to 2010, and Elan Pharmaceuticals from February 2005 to February 2008, where they held the position of Senior Director in the Epidemiology & Pharmacoeconomics Department.

Will Maier has a Bachelor's degree in Biochemistry and Cell Biology from UC San Diego. Will then went on to pursue a Master's degree in Epidemiology and Biostatistics at San Diego State University. After that, they earned a Postgraduate Diploma in Organizational Development/Tavistock Institute from City, University of London. Finally, they completed their education with a PhD in Epidemiology from the University of North Carolina at Chapel Hill.